HLB Co., Ltd.
028300
Rank in Stocks
#4131
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
Share Price
$29.60
Market Cap
$3.93B
Change (1 day)
-0.35%
Change (1 year)
-7.48%
Country
KR
Trade HLB Co., Ltd. (028300)
Category
Healthcare
P/E ratio for HLB Co., Ltd. (028300)
P/E ratio as of October 2026 TTM: -25.11
According to HLB Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -25.11. At the end of 2023 the company had a P/E ratio of -34.11.
P/E ratio history for HLB Co., Ltd. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -25.11 | -75.83% |
| 2024 | -103.87 | 204.51% |
| 2023 | -34.11 | -10.88% |
| 2022 | -38.28 | -1.65% |
| 2021 | -38.92 | -40.32% |
| 2020 | -65.21 | -40.07% |
| 2019 | -108.82 | -191.18% |
| 2018 | 119.35 | -221.79% |
| 2017 | -98.00 | 152.42% |
| 2016 | -38.82 | -165.13% |
| 2015 | 59.61 | -144.21% |
| 2014 | -134.81 | 1,491.04% |
| 2013 | -8.47 | -16.87% |
| 2012 | -10.19 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -214.64% |
US
|
|
| -28.36 | 12.95% |
US
|
|
| -24.57 | -2.15% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -220.80% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.